1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanomaReinhard Dummer, Georgina V. Long, Roni Shapira et al.|Annals of Oncology|2024Cited by 3